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ABSTRACT Acute respiratory distress syndrome (ARDS) has a significant impact on post-operative
morbidity and mortality following oesophagectomy. Smoking is a risk factor for the development of
ARDS, although the mechanism is unclear. We examined the effect of smoking on alveolar and systemic
inflammation, in addition to alveolar–capillary permeability, leading to ARDS in patients undergoing
oesophagectomy.
We compared clinical, biomarker and PiCCO system data between current smokers (n=14) and ex-
smokers (n=36) enrolled into a translational substudy of the BALTI-P (Beta Agonist Lung Injury Trial
Prevention) trial.
Current smokers compared with ex-smokers had significantly higher numbers of circulating neutrophils,
elevated bronchoalveolar lavage (BAL) interleukin (IL)-1 receptor antagonist (IL-1ra), soluble tumour
necrosis factor receptor-1 and pre-operative plasma soluble intercellular adhesion molecule-1, and lower
BAL vascular endothelial growth factor and post-operative plasma IL-17 (p<0.05). On post-operative day
1, current smokers had higher extravascular lung water index (9.80 versus 7.90; p=0.026) and pulmonary
vascular permeability index (2.09 versus 1.70; p=0.013). Current smokers were more likely to develop
ARDS (57% versus 25%; p=0.031) and had a significantly reduced post-operative median survival (421
versus 771 days; p=0.023).
Smoking prior to oesophagectomy is associated with dysregulated inflammation, with higher
concentrations of inflammatory mediators and lower concentrations of protective mediators. This
translates into a higher post-operative inflammatory alveolar oedema, greater risk of ARDS and poorer
long-term survival.
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Introduction
Oesophagectomy is associated with a high burden of post-operative morbidity and mortality with
attendant long-term health and economic costs [1–4]. Post-operative pulmonary complications including
acute respiratory distress syndrome (ARDS) are common, and contribute significantly to the burden of
post-operative morbidity and mortality [5, 6]. The reported incidence of ARDS post-oesophagectomy is
variable and the reasons behind this heterogeneity are not clear. The reported incidence in the BALTI-P
(Beta Agonist Lung Injury Trial Prevention) trial from which the cohort in this current study was drawn
was 25.3% [7].
Smoking has recently been identified as a risk factor for the development of ARDS in nonpulmonary
sepsis, following trauma and lung transplant [8–10]. The mechanism underlying this association is
unclear, although cigarette smoke exposure is known to adversely alter the permeability of the pulmonary
epithelium [11] and endothelium [12], and increase alveolar inflammation [13]. Recent evidence has
demonstrated that smokers have an exaggerated disruption of the alveolar–capillary membrane and
dysregulated cytokine release in response to nebulised Escherichia coli lipopolysaccharide compared with
nonsmokers [14].
No clear association has been demonstrated between smoking and the risk of ARDS following
oesophagectomy. This study compared pre- and post-operative plasma biomarkers, post-operative
bronchoalveolar lavage (BAL) fluid biomarkers, and PiCCO system measures of alveolar oedema between
smokers and nonsmokers undergoing oesophagectomy, aiming to assess the relationship between
pre-operative smoking status and post-operative ARDS and mortality. It was hypothesised that current
smokers would have higher BAL inflammatory markers, higher measures of alveolar oedema, and higher
post-operative ARDS and mortality.
Methods
Study subjects
Data from ex-smokers and current smokers enrolled into a translational substudy of the BALTI-P trial
were included [7, 15]. Patients with unresectable disease at surgery were excluded from analysis. Patients
were asked to self-report their smoking status at the pre-operative assessment clinic 1–2 weeks prior to
surgery. Current smokers were defined as patients who were self-reported cigarette smokers at the
pre-operative assessment clinic. Ex-smokers were defined as patients who stated they had smoked in the
past but no longer did so. The small number of patients who had never smoked were excluded from
the analysis (n=6).
Data collection
Clinical and demographic data were collected prospectively from the patient’s medical records. Full blood
counts taken as part of routine clinical care were compared to investigate the level of systemic
inflammation in the immediate post-operative period. Not all patients had blood drawn for full blood
count on each post-operative day. BAL samples were collected at the end of the operation before
extubation using the methods previously described [16]. Supernatant was extracted by centrifugation and
analysed. The BAL supernatant was frozen at −80°C and batch analysis of levels of cytokines, including
interleukin (IL)-1 receptor antagonist (IL-1ra), IL-1β, IL-6, IL-8, surfactant protein D (SPD), soluble
receptor for advance glycation end-products (RAGE), tumour necrosis factor (TNF)-α, soluble TNF
receptor-1 and -2 (TNFR1 and TNFR2), and vascular endothelial growth factor (VEGF), determined using
Luminex technology (Millipore, Billerica, MA, USA). PiCCO readings (Pulsion, Feldkirchen, Germany),
including cardiac index, extravascular lung water index (EVLWI) and pulmonary vascular permeability
index (PVPI), were measured immediately pre-operatively, immediately post-operatively and on the
morning after the operation (post-operative day 1). As this cohort of patients was diagnosed prior to the
publication of the Berlin criteria, throughout the paper we have used ARDS to indicate patients meeting
criteria for acute lung injury or ARDS according to the definition of the American European Consensus
Conference [17].
Statistical analysis
Data were analysed using Prism version 6 (GraphPad, La Jolla, CA, USA). Continuous data were analysed
for normality using the D’Agostino–Pearson omnibus normality test, and the appropriate parametric or
nonparametric test was performed to detect differences in biochemical and clinical outcomes between
current and ex-smokers at the time of the operation. Categorical data were assessed using the Chi-squared
test. Survival was analysed using a Kaplan–Meier survival curve, the Gehan–Breslow–Wilcoxon test and
log-rank hazard ratio assessment.
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Results
50 patients (14 current smokers and 36 ex-smokers) were included. Baseline data comparisons between
current and ex-smokers are summarised in table 1. Current smokers were statistically more likely to be
younger, with a lower body mass index (BMI) than ex-smokers. There was no significant difference in sex,
forced expiratory volume in 1 s (FEV1) % pred or FEV1/forced vital capacity ratio between current and
ex-smokers. There was no significant difference in any of three pre-operative risk assessment scores, i.e.
modified Glasgow Prognostic Score, pre-operative neutrophil/lymphocyte ratio or pre-operative platelet/
lymphocyte ratio.
Circulating neutrophil count
Current smokers had significantly higher numbers of circulating neutrophils on post-operative days 1–3
with no significant difference in lymphocyte or platelet count (figure 1).
Biochemical data
An insufficient BAL sample for analysis was obtained in one patient. Current smokers had higher
numbers of alveolar macrophages in BAL fluid than ex-smokers (median (interquartile range (IQR))
100029 (40178–178043) versus 45000 (24146–73260) cells·mL−1; p=0.025). In contrast to the plasma
compartment, there was no significant difference in numbers of BAL neutrophils between current smokers
and ex-smokers (median (IQR) 18996 (1128–91800) versus 4378 (740–90909) cells·mL−1; p=0.517).
Current smokers had significantly higher concentrations of IL-1ra (median (IQR) 51.0 (27.8–123.8) versus
10.1 (0.2–64.6) pg·mL−1; p=0.008) and TNFR1 (median (IQR) 270.5 (168.5–367.3) versus 166.8
(112.4–253.1) pg·mL−1; p=0.030), and significantly lower levels of VEGF (median (IQR) 94.1 (24.0–184.1)
versus 151.0 (104.4–280.4) pg·mL−1; p=0.018) in BAL fluid compared with ex-smokers (figure 2). Current
smokers had significantly higher pre-operative plasma concentrations of soluble intercellular adhesion
molecule (ICAM)-1 than ex-smokers (median (IQR) 103.5 (63.9–133.0) versus 56.0 (35.1–86.4) pg·mL−1;
p=0.003), but there was no significant difference post-operatively. Plasma concentrations of IL-17 were
generally lower in current smokers than ex-smokers, with a significant difference post-operatively (median
(IQR) 2.64 (0.52–182.8) versus 36.8 (6.12–192.6) pg·mL−1; p=0.043). There was no significant difference in
TABLE 1 Summary of baseline characteristics of current and ex-smokers at the time of
operation
Ex-smokers Current smokers p-value
Subjects 36 14
Male 31 (86) 13 (93) 0.663
Age years 65.5±9.7 51.9±8.1 <0.0001
BMI kg·m−2 26.0 (23.8–28.4) 22.0 (18.2–24.7) 0.002
FEV1 % pred 82.8±23.3 93.1±21.2 0.153
FEV1/FVC % 68.5 (61.9–75.4) 63.6 (52.4–70.3) 0.086
Pack-years 31.1 (17.7) 49.6 (30.5) 0.010
Histological diagnosis
Adenocarcinoma 28 (77.7) 9 (64.3) 0.473
Squamous 8 (22.3) 5 (35.7)
Tumour location
Lower oesophagus 27 (75) 9 (64.2) 0.724
Upper or mid oesophagus 6 (16.7) 3 (21.4)
Unknown 3 (8.3) 2 (14.3)
Cancer staging
IB, IIA or IIB 15 (41.7) 6 (42.9) 0.939
IIIA 21 (58.3) 8 (57.1)
ASA grade
2 26 (72.2) 13 (92.9) 0.148
3–4 10 (27.8) 1 (7.1)
mGPS=1 5 (14) 3 (21) 0.670
Pre-operative NLR 2.75 (2.07–3.15) 2.61 (1.68–3.12) 0.479
Pre-operative PLR 163.3 (130.7–207.3) 160.3 (113.4–252.6) 0.613
Data are presented as n, n (%), mean±SD or median (interquartile range), unless otherwise stated. BMI:
body mass index; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; ASA: American Society
of Anesthesiologists; mGPS: modified Glasgow Prognostic Score; NLR: neutrophil/lymphocyte ratio; PLR:
platelet/lymphocyte ratio.
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levels of total protein, soluble RAGE, SPD, IL-6, IL-8, IL-1β, TNF-α or TNFR2 between the groups
(supplementary tables E1–E4).
PiCCO measures of alveolar oedema
EVLWI, PVPI and the arterial oxygen tension (PaO2)/inspiratory oxygen fraction (FIO2) ratio were similar
between both groups pre- and post-operatively (figure 3). EVLWI (median (IQR) 9.80 (7.80–12.18) versus
7.90 (6.25–10.25) mL·kg−1; p=0.026) and PVPI (median (IQR) 2.09 (1.78–2.50) versus 1.70 (1.45–2.01);
p=0.013) were significantly higher in current smokers than ex-smokers on post-operative day 1. There was
no significant difference in the PaO2/FIO2 ratio on post-operative day 1 (mean±SD current smokers
36.7±10.7 versus ex-smokers 42.8±10.7 kPa; p=0.072). There was no significant difference in the cardiac
index at any time-point (supplementary table E5).
Clinical outcomes
Of the 50 patients, 33 (66%) patients required ventilation after surgery with a median positive
end-expiratory pressure of 5 cmH2O. On post-operative day 1 only three (6%) patients remained ventilated
after surgery. There was no significant difference between groups in the requirement for ventilation after
surgery (23 (64%) ex-smokers versus 10 (71%) current smokers; p=0.75) or on post-operative day 1 (two
(6%) ex-smokers versus one (7%) current smoker; p=1.0). There was no significant difference between the
intra-operative fluid balance between the two groups (median (IQR) ex-smokers 2330 (1888–3375) mL
versus current smokers 2400 (1189–3088) mL; p=0.347).
A total of 17 patients (34%) developed ARDS post-operatively. Eight (57%) current smokers developed
ARDS post-operatively compared with nine (25%) ex-smokers (p=0.031) (figure 4). There was no
significant difference in the risk of post-operative pneumonia between current smokers and ex-smokers
(35.7% versus 27.8%; p=0.582). There was also no significant difference in the length of hospital admission
between current smokers and ex-smokers (median (IQR) 14 (8–25) versus 15 (10–25) days; p=0.4487).
Current smokers had a significantly higher mortality post-operatively than ex-smokers, with a median
post-operative survival of 421 days in current smokers compared with 771 days in ex-smokers (p=0.0225)
(figure 5); the log-rank HR was 2.034 (95% CI 1.012–5.298). Patients were followed-up for up to 4 years
after surgery, with a significant difference in survival being seen from 9 months post-operatively
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current smokers than ex-smokers. #: time-points were statistically significant using multiple t-tests with the
Holm–Šídák method (α=5.0%) to account for multiple comparisons.
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(ex-smokers two out of 28 (7%) mortality at 9 months versus current smokers five out of 14 (36%)
mortality at 9 months; p=0.031).
Discussion
This work demonstrates that patients who continue to smoke prior to oesophagectomy have greater
post-operative systemic and lung inflammation evidenced by increased numbers of circulating neutrophils,
alveolar oedema, and dysregulated concentrations of cytokines in plasma and BAL fluid compared with
ex-smokers. Clinically, this translated into worse outcomes with both higher rates of post-operative ARDS
and long-term mortality.
Smoking has been linked to an increased risk of ARDS in a variety of conditions, including sepsis and
trauma, but the mechanism is not entirely clear [8, 9, 14]. Smoking has been demonstrated to increase
both epithelial and endothelial permeability [11, 12], and to be associated with increased alveolar oedema;
studies in explanted human lungs found that smokers have more alveolar oedema as measured by lung
weight than nonsmokers and that smokers with the highest level of smoke exposure have impaired alveolar
fluid clearance [18]. A recent study in healthy volunteers using the lipopolysaccharide challenge model of
ARDS suggested that smoking may predispose to an exaggerated disruption of the alveolar–capillary
membrane in response to inflammatory insults [14], increasing the permeability of the membrane to
protein and replicating findings seen in ARDS. Increased pulmonary permeability appears to be rapidly
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FIGURE 2 There was no difference in bronchoalveolar lavage (BAL) a) neutrophil counts between current
smokers (n=14) and ex-smokers (n=35), but current smokers had significantly higher concentrations of b)
macrophages, c) interleukin-1 receptor antagonist (IL-1ra) and d) tumour necrosis factor receptor-1 (TNFR1),
and lower concentrations of e) vascular endothelial growth factor (VEGF), than ex-smokers.
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reversible, with one study demonstrating that the pulmonary epithelial permeability induced by smoking
improves within 1 week of smoking cessation [19].
Current smokers in our study had greater levels of inflammatory alveolar oedema as demonstrated by
greater post-operative day 1 EVLWI and PVPI, and higher concentrations of IL-1ra and TNFR1, than
ex-smokers. Previous studies have demonstrated a higher concentration of BAL IL-1ra and TNFR1 in
patients at risk of ARDS, and in those with active ARDS [20, 21]. Higher circulating TNFR1
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concentrations are also associated with poorer outcomes in patients with ARDS [22]. Meanwhile, BAL
VEGF, which acts to protect the pulmonary vasculature and epithelium, was lower in current smokers.
Again, low concentrations of BAL VEGF are commonly seen in patients with ARDS [23, 24]. In plasma,
pre-operative concentrations of soluble ICAM-1, an endothelial cell adhesion molecule that has been
shown to be elevated in smokers and associated with poorer prognosis in patients with colorectal cancer
[25, 26], were greater in current smokers, but there was no significant difference in post-operative levels.
Concentrations of IL-17 were lower in current smokers, a finding which has previously been associated
with increased susceptibility to bacterial colonisation in the lungs [27]. Taken together, these findings
suggest that the dysregulated inflammation in smokers leads to increased alveolar oedema, ARDS and
death post-operatively.
To the best of our knowledge, this study is the first to investigate the relationship between pre-operative
smoking status and PiCCO measures of peri-operative alveolar oedema. We found that smokers have
evidence of dysregulated alveolar inflammation in the peri-operative period as a direct effect of surgical
trauma, which may explain the increased risk of post-operative ARDS. Our finding that risk of pneumonia
was similar in both groups suggests that the increased risk of ARDS in smokers undergoing
oesophagectomy is not a result of increased susceptibility to pulmonary infection, but perhaps due to a
dysregulated response to inflammatory insult.
We found that ex-smokers survive on average almost 1 year longer (350 days) following oesophagectomy
than current smokers. We were unable to access death certificate records to establish the cause of death for
our patients, but it is likely to include recurrence of the oesophageal cancer and infection. Patients
diagnosed with ARDS have increased mortality for at least 2 years following recovery from their acute
illness [28], so the increased incidence of ARDS we found in current smokers may directly contribute to
increased long-term mortality. There is little data available on the effects of ARDS upon long-term
immunoparesis, but studies in patients with sepsis have demonstrated marked effects on the adaptive
immune system that may increase susceptibility to development of disease in the future [29, 30].
This study does have limitations. First, it is likely that some differences between groups are obscured by
the small number of patients studied. The patients in this study only had post-operative BAL performed,
so we were not able to investigate smoking-related changes from pre-operative BAL prior to
oesophagectomy. Furthermore, data related to modes of ventilation, ventilator settings and lung protective
ventilation during anaesthesia were not collected in these patients, all of which may play a role in
decreasing the rate of post-operative complications and mortality. In addition, patients self-reported their
smoking status and we were not able to carry out any biochemical confirmation (e.g. exhaled carbon
monoxide and salivary cotinine), which may have increased the accuracy of the assessment [31]. We do
not know the length of time since smoking cessation for the group of ex-smokers and it is likely that the
range is relatively broad. Data regarding smoking status were collected at the pre-operative assessment
clinic (typically up to 2 weeks prior to surgery) and self-reported, so it is possible that some short-term
quitters were included in the current smokers group. There is little consensus on the optimal minimal
time prior to surgery for cessation; while studies have shown that airway sensitivity is reduced within
1–2 days of abstinence from smoking [32], others suggest that a period of time ranging from 1 to
6 months is required to see a reduction in post-operative pulmonary complications [33–37]. While some
studies have suggested an increased risk of harm when smokers abstain or reduce cigarette consumption
close to surgery, this has not been confirmed on meta-analysis, although the number of patients involved
in such studies is relatively small [36, 38].
FIGURE 5 Post-operative mortality
was significantly higher in patients
who were current smokers prior to
surgery compared with ex-smokers
(p=0.0225).
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Conclusions
This study demonstrates that patients who smoke at the time of oesophagectomy have altered pulmonary
immune markers post-operatively, with higher levels of inflammatory mediators, and lower levels of
protective mediators, similar to those seen in established ARDS. These changes translate into a higher
post-operative inflammatory alveolar oedema, greater risk of ARDS and greater long-term mortality.
Further research is needed to investigate the optimal timing of smoking cessation prior to surgery, and to
evaluate the impact that novel nicotine delivery systems such as “e-cigarettes” have on post-operative
inflammation and clinical outcomes.
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